us fda is investigating the safety of trt, page-22

The AFR article suggests the maquarie broker is getting himself all excited over not much. If anything the review is likely to benefit ACL delivery method without affecting existing patients or their main target group. Nothing to see here. Probably not going to see any sharp recovery because the market is being a dik but if you are shorting it the intellectual basis for the short has gone up in smoke so you are just gambling from here. You still might win but who knows. Note in the AFR article the last line is out of date as it has an analyst forecasting December sales of $41m compared to the 50m it in fact was. If the heart disease link is scaring anyone it is not evident from that figure.